Project Details
Description
"Among patients early following ST-segment (ST) elevation myocardial infarction, transcutaneous vagus nerve stimulation is associated with a reduce of the burden of premature ventricular contractions in the first 40 days post-myocardial infarction (MI).
The above hypothesis will be tested with a randomized, prospective, parallel, single-blind clinical trial. The expected study duration is approximately 12 months from the time the first subject is enrolled (planned for June 2023) to the time of study's termination date (December 2024). Patient enrollment is planned to take place at two major centers in Greece. The researchers will obtain approval by the institutional review board (IRB)."
The above hypothesis will be tested with a randomized, prospective, parallel, single-blind clinical trial. The expected study duration is approximately 12 months from the time the first subject is enrolled (planned for June 2023) to the time of study's termination date (December 2024). Patient enrollment is planned to take place at two major centers in Greece. The researchers will obtain approval by the institutional review board (IRB)."
| Acronym | EARLY-VAGUS |
|---|---|
| Status | Finished |
| Effective start/end date | 30/06/23 → 31/12/24 |
Collaborative partners
- Hippocration General Hospital of Athens, Greece Mehmet Sarıkaya (lead)
- Abu Dhabi Health Services Company
Keywords
- transcutaneous vagal nerve stimulation
- Ischemia
- Pathologic Processes
- Necrosis
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arrhythmias, Cardiac
- Cardiac Conduction System Disease
- Myocardial Infarction
- Tachycardia
- Infarction
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.